General Information of Drug (ID: DM6KRJW)

Drug Name
BEA-005 Drug Info
Synonyms
HMddC; BEA-005; 3'-Hydroxymethyl-ddC; UNII-C7BPP68MLT; C7BPP68MLT; 2',3'-Dideoxy-3'-hydroxymethyl cytidine; 132235-73-5; AC1L9PVF; SCHEMBL598443; DTXSID60157443; 1-(2',3'-Dideoxy-3'-C-(hydroxymethyl)-beta-D-erythro-pentofuranosyl)cytosine; 2',3'-dideoxy-3'-c-(hydroxymethyl)cytidine; 4-amino-1-[(2R,4R,5S)-4,5-bis(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 1-[2',3'-Dideoxy-3'-C-(hydroxymethyl)-.beta.-D-erythro-pentofuranosyl]cytosine
Indication
Disease Entry ICD 11 Status REF
Cytomegalovirus infection 1D82 Terminated [1]
Cross-matching ID
PubChem CID
451819
CAS Number
CAS 132235-73-5
TTD Drug ID
DM6KRJW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [3]
Nevirapine DM6HX9B Human immunodeficiency virus infection 1C62 Approved [4]
Zalcitabine DMH7MUV Human immunodeficiency virus infection 1C62 Approved [5]
Tenofovir DM1IS6U Chronic hepatitis B virus infection Approved [3]
Lamivudine DMI347A Chronic HBV infection 1E51.0Z Approved [6]
Abacavir DMMN36E Human immunodeficiency virus infection 1C62 Approved [7]
Delavirdine DM3NF5G Human immunodeficiency virus infection 1C62 Approved [6]
Efavirenz DMC0GSJ Human immunodeficiency virus infection 1C62 Approved [6]
Rilpivirine DMJ0QOW Human immunodeficiency virus infection 1C62 Approved [8]
Etravirine DMGV8QU Human immunodeficiency virus-1 infection 1C62 Approved [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Reverse transcriptase (HIV RT) TT84ETX POL_HV1B1 Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008999)
2 Efficacy of Postexposure Prophylaxis after Intravaginal Exposure of Pig-Tailed Macaques to a Human-Derived Retrovirus (Human Immunodeficiency Virus Type 2). J Virol. 2000 October; 74(20): 9771-9775.
3 Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
4 HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
5 A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
8 Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
9 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.